Discovery of a novel, selective brain penetrant CDK2 inhibitor for targeted cancer therapy

Written By Guest User
Download Poster
Guest User
Previous

ZE74-0282 is a novel JAK2 JH2 domain inhibitor with promising preclinical activity in JAK2V617F mutant diseases
Next

A Novel, wild-type sparing pan-EGFR Inhibitor (ZE77-0273) with Broad Activity Against Resistance Mutations in EGFR-Mutant NSCLC